Intelligence · Clinical Development
Pipeline search results
Programs matching “treatment” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 270 pipeline programs matching "treatment" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ABP-2019
The George Institute
locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC
1 trial -
AL8326
Lacuna Pharma Pty Ltd
Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.
1 trial -
AL8326
Lacuna Pharma Pty Ltd
- Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.
1 trial -
ALECTINIB
Hoffmann-La Roche
ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available
1 trial -
APLOaß-NB
Istituto Gentili S.r.l.
Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.
1 trial -
AUTO-LT1
Autolus GmbH
Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.
1 trial -
AXS-05
Axsome Therapeutics
Treatment Resistant Depression
1 trial -
AXS-05 (dextromethorphan-bupropion)
Axsome Therapeutics
Treatment Resistant Depression
1 trial -
Active Treatment- CT1812 100 mg
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Active treatment with a high dose of BGS649
Mereo BioPharma Group plc
Endometriosis
1 trial -
Adtralza 150 mg solution for injection in pre-filled syringe
LEO Pharma A/S
Treatment of moderate-to-severe Atopic dermatitis
1 trial -
Anterior lamellar nanostructured artificial human cornea.
Lxo Ireland Designated Activity Company
Severe Trophic Corneal Ulcers Refractory to Conventional Treatment
1 trial -
Atacicept Autoinjector Combination, Atacicept
Vera Therapeutics
Treatment of IgAN
1 trial -
BRII-179
Vir Biotechnology
For Treatment of Chronic Hepatitis B Virus Infection
1 trial -
C3601010
Pfizer Australia Pty Ltd
Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection
1 trial -
CAPTURE
Fondazione Telethon ETS
Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies
1 trial -
CAR-T treatment
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
CC-486-NSCL-001
Celgene Europe Limited
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
1 trial -
CD25 antibody combined glucocorticoid as first-line treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Graft Versus Host Disease
1 trial -
CIALIS 5 mg film-coated tablets
The George Institute
sexual/ erectile function in women and men after treatment for rectal cancer
1 trial -
CND261
Lacuna Pharma Pty Ltd
Active, treatment refractory, ANCA-IgG-positive associated vasculitis
1 trial -
CSET 2022-3571
The George Institute
Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.
1 trial -
CYTB323O12101
Novartis Pharmaceuticals
Treatment-resistant generalized Myasthenia Gravis
1 trial -
Cizutamig
Lacuna Pharma Pty Ltd
Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.